Cue Biopharma gets FDA fast track status for CUE-101 in HPV16+ R/M HNSCC
Cue Biopharma has been granted fast track designation for CUE-101 from the US Food and Drug Administration (FDA) for the treatment of a type of head and neck squamous cell carcinoma (HNSCC) both as a monotherapy and in combination with Merck’s pembrolizumab (KEYTRUDA). The fast track designation for the interleukin 2 (IL-2)-based biologic is in […]